688189，被证监会立案调查！重大资产重组终止！

Core Points - Nanjing Pharmaceutical (688189) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, leading to a formal investigation [2] - The planned major asset restructuring has been terminated, which was initially aimed at acquiring assets from Future Medicine for up to 480 million yuan [3] - The company reported a revenue of 61.8463 million yuan and a net loss of 40.0023 million yuan in the first half of the year [2] Group 1 - The CSRC issued a notice of investigation to Nanjing Pharmaceutical due to alleged violations in annual report disclosures [2] - The company will cooperate with the CSRC during the investigation and will fulfill its information disclosure obligations as required by law [2] - The planned acquisition of Future Medicine was announced on August 27, 2025, but the parties could not reach an agreement on core terms, leading to the termination of the restructuring plan [3] Group 2 - Nanjing Pharmaceutical emphasized that the termination of the asset restructuring will not adversely affect its business operations or financial status [3] - The company plans to continue pursuing its strategic goals and seek development opportunities through investments, mergers, and collaborations to enhance its product offerings and profitability [4]